Free Trial

Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis

+0.74 (+6.26%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
311,378 shs
Average Volume
403,081 shs
Market Capitalization
$551.13 million
P/E Ratio
Dividend Yield
Price Target

Y-mAbs Therapeutics MarketRank™ Stock Analysis

Analyst Rating
2.33 Rating Score
38.0% Upside
$17.33 Price Target
Short Interest
7.47% of Float Sold Short
Dividend Strength
News Sentiment
-0.04mentions of Y-mAbs Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$28,283 Sold Last Quarter
Proj. Earnings Growth
From ($0.45) to ($0.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.92 out of 5 stars

Medical Sector

555th out of 921 stocks

Pharmaceutical Preparations Industry

248th out of 416 stocks

YMAB stock logo

About Y-mAbs Therapeutics Stock (NASDAQ:YMAB)

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

YMAB Stock Price History

YMAB Stock News Headlines

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 6.8%
Y-mAbs: There's A Ceiling Here Somewhere
Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
Y-mAbs to Present at 2024 ASCO Annual Meeting
Y-mAbs Therapeutics Finance Chief Bo Kruse Resigns
Y-mAbs Therapeutics CFO Bo Kruse To Retire
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call
See More Headlines
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$84.82 million
Book Value
$2.32 per share


Free Float
Market Cap
$528.32 million
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

YMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings
or view top-rated stocks.

What is Y-mAbs Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued twelve-month price targets for Y-mAbs Therapeutics' shares. Their YMAB share price targets range from $5.00 to $26.00. On average, they anticipate the company's share price to reach $17.33 in the next year. This suggests a possible upside of 38.0% from the stock's current price.
View analysts price targets for YMAB
or view top-rated stocks among Wall Street analysts.

How have YMAB shares performed in 2024?

Y-mAbs Therapeutics' stock was trading at $6.82 on January 1st, 2024. Since then, YMAB stock has increased by 84.2% and is now trading at $12.56.
View the best growth stocks for 2024 here

When is Y-mAbs Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our YMAB earnings forecast

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) announced its earnings results on Thursday, February, 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.17. The business had revenue of $23.36 million for the quarter, compared to analyst estimates of $21.72 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 21.40% and a negative net margin of 25.64%.

What ETFs hold Y-mAbs Therapeutics' stock?

ETFs with the largest weight of Y-mAbs Therapeutics (NASDAQ:YMAB) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

What guidance has Y-mAbs Therapeutics issued on next quarter's earnings?

Y-mAbs Therapeutics updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $95.0 million-$100.0 million, compared to the consensus revenue estimate of $97.2 million.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

Y-mAbs Therapeutics (YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.72%), Acadian Asset Management LLC (1.37%), Jacobs Levy Equity Management Inc. (0.35%), Los Angeles Capital Management LLC (0.29%), Price T Rowe Associates Inc. MD (0.05%) and Caxton Associates LP (0.04%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, Johan Wedell-Wedellsborg, Thomas Gad and Vignesh Rajah.
View institutional ownership trends

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YMAB) was last updated on 5/21/2024 by Staff

From Our Partners